Антибіотикорезистентність клінічних штамів Enterococcus faecalis у хірургічних стаціонарах України: результати багатоцентрового дослідження (2011-2015)
| Autor: | A.Yu. Usenko, A. G. Salmanov |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Imipenem biology business.industry Sulbactam biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Meropenem Enterococcus faecalis Cefoperazone chemistry.chemical_compound chemistry Internal medicine Linezolid polycyclic compounds medicine Vancomycin business Cefuroxime medicine.drug |
| Zdroj: | International Journal of Antibiotics and Probiotics. 1:30-47 |
| ISSN: | 2616-7484 |
| DOI: | 10.31405/ijap.1-2.17.02 |
| Popis: | Objective — to study the activity of antimicrobials against nosocomial strains of Enterococcus faecalis, isolated in the surgical hospitals of different regions of the Ukraine. Materials and methods. A total of 87273 nosocomial strains of E. faecalis isolated in 2011—2015 from patients hospitalized in 47 surgical hospitals in 24 different regions of Ukraine. Susceptibility to 34 antimicrobials: penicillum, ampicillin, amoxicillin, oxacillin, ampicillin/sulbactam, amoxicillin/clavulanic acid, cefazolin, cefalexin, cefuroxime, cefoperazone, cefotaximum, ceftriaxone, ceftazidime, cefepim, imipenem, meropenem, gentamicin, amikacinum, eritromicin, clarithromycin, azithromycin, lincomycin, clindamycin, tetracyclin, doxycyclinum, vancomycin, ofloxacinum, levofloxacin, gatifloxacin, ciprofloxacin, norfloxacin, pefloxacin, linezolid was determined by agar dilution method in accordance with the CLSI (Clinical and Laboratory Standards Institute) recommendations. Results and discussion. Studies have shown that in surgical hospitals in Ukraine, 37 % of E. faecalis strains showed resistance to tested antibiotics. The most potent antimicrobials were linezolid, vancomycin, meropenem, levofloxacin and imipenem. The high rates of resistance were found to cefalexin (56.4 %), penicillum (47.9 %), cefuroxime (47.4 %), cefoperazone (47.0 %), norfloxacin (43.1 %), clarithromycin (42.6 %), ceftazidime (41.6 %), doxycyclinum (40.5 %), clindamycin (39.7 %), cefotaximum (39.5 %), amikacinum (38.1 %), gentamicin (37.4 %), and to azithromycin (37.6 %). The frequency of isolation of vancomycin- resistant E. faecalis (VRE) among tested strains was 20.8 % varying from 8.0 % to 49.4 % in surgical hospitals of different regions. Conclusions. Resistance of clinical strains of E. faecalis at in-patient medical institutions, that are subject to research, is a serious therapeutic and epidemiologic issue. Linezolid, vancomycin, meropenem, levofloxacin, and imipenem have been the most active to nosocomial strains of E. faecalis. Taking into account resent changes and resistance levels of nosocomial strains of E. faecalis, which take place in various regions, constant monitoring over resistance to antimicrobials at every in-patient medical institution is required. Also, hospital record sheets of antibiotics should be elaborated based upon the local data received. Antibiotics utilization policy in each surgical in patient institution should be determined based in accordance with the local data on resistance to antimicrobials. System of epidemiologic surveillance over microbial resistance should be established on the local, regional, and national level. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|